Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Bako Diagnostics Appoints Ted Hull as Chief Executive Officer

Bako Diagnostics
Posted on: 25 Jul 18

ATLANTA, July 24, 2018 /PRNewswire/ -- Bako Diagnostics, a podiatry-focused clinical laboratory and products company, announced today the appointment of Ted Hull as Chief Executive Officer, effective August 1, 2018. Mr. Hull succeeds Larry McCarthy, Chairman of Bako Diagnostics, who has also served as interim Chief Executive Officer since August 2017.

Mr. Hull, an experienced executive with a proven track record of leading high-performing businesses, brings more than 25 years of industry experience and a wealth of expertise and successes to Bako Diagnostics. Previously, he spent 15 years, from 2000-2015, at Genova Diagnostics, a leading company in applying a systems-based approach in clinical laboratory testing for the diagnosis, treatment and prevention of complex chronic disease, where he served as both Chief Financial Officer and then Chairman and Chief Executive Officer. Mr. Hull was credited with developing and leading the execution of the strategy that grew the company into a world leader. Most recently, Mr. Hull served as Managing Partner of Ramble Ventures, a private investing company in Asheville, North Carolina, where he advised investors on acquisition opportunities in small, growth-focused healthcare services companies.

"I am excited to welcome Ted to Bako Diagnostics, a market leading pathology laboratory with an unwavering commitment to podiatric medicine, as evidenced through broad educational support of the profession and a commitment to quality, service and the development of new products and offerings," said Larry McCarthy, Chairman and interim Chief Executive Officer. "Ted is a proven leader, with significant expertise in the specialty laboratory industry and he is ideally suited to steer Bako Diagnostics through its next corporate chapter. Along with the management team and the rest of the Board, I look forward to working with Ted in this capacity."

"It is an honor to join Bako Diagnostics, a company dedicated to bringing its customers and their clients the highest quality laboratory services and products, while supporting the continuing education and growth of professionals across the industry," said Mr. Hull. "The seasoned team at Bako Diagnostics is unrivaled in their experience, expertise and commitment to the podiatric community and I am eager to build on their success as we continue to execute on the company's long-term strategic objectives and growth plans."   

About Bako Diagnostics

Bako Diagnostics is a provider of diagnostic and therapeutic services for the Podiatric Medical Community with a unique focus on pathology of the lower extremity. Bako's comprehensive testing menu includes ENFD Analysis, Mass Spectrometry, for rapid identification of bacteria from culture specimens, and Molecular Genetics for the detection of micro-organisms and as a diagnostic aid in certain pathologic diagnoses. Bako's in-network services are available through its more than 250 million covered lives, including all five national health plans and fully compliant patient-friendly billing policies. Over the past nine years, Bako has evolved into one of the podiatric profession's principal sources of educational sponsorship.

About Ted Hull

Ted Hull brings 25 years of industry experience with him and a wealth of experience and successes to Bako Diagnostics. Most recently, Mr. Hull served as Managing Partner of Ramble Ventures, a private investing company in Asheville North Carolina, where he advised investors on acquisition opportunities in small, growth-focused healthcare services companies. Prior to that, Mr. Hull worked for Eurofins Scientific, a European company that owns and operates many industry and clinical laboratories across the globe, where he oversaw their US clinical laboratory operations that included Viracor-IBT, Diatherix and Emory Genomics Laboratory.  

Mr. Hull spent 15 years, from 2000-2015, at Genova Diagnostics, a leading company in applying a systems-based approach in clinical laboratory testing for the diagnosis, treatment and prevention of complex chronic disease, where he served as both Chief Financial Officer and then Chairman and Chief Executive Officer. He began his career in public accounting at Deloitte, and later spent seven years with Nichols Institute at Quest Diagnostics in various finance and business development leadership positions. Mr. Hull is a graduate of the University of Pennsylvania's Wharton School of Business with a BS in Economics.

Media Contact

Ed Trissel / Jon Keehner / Kate Clark

Joele Frank, Wilkinson Brimmer Katcher

212-355-4449

kclark@joelefrank.com

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 25/07/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.